CancerGeneticsGenetic
What this study is
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
What's being tested
- KRAS-variant and microRNA binding site mutation testing
Intervention · GENETIC
Participant in these studies will be tested for the KRAS-variant
Study details
- Sponsor
- MiraKind
- Conditions
- Cancer
- Enrolling
- 15,000 people
- Starts
- 2014-09
- Est. completion
- 2035-09
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers AcceptedYou may qualify if
- Personal or family history of cancer
- Personal history of endometriosis, or autoimmunity
You can't join if
- Younger than 18
- Non-english speaking and unable to understand and sign the consent
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openMiraKind
Los Angeles, California, United States
- Joanne Weidhaas, MDPhD · Contact203-671-1308joanne@mirakind.org
- Joanne Weidhaas · Contact424-387-8100
Recruiting
Study team
Sponsor
MiraKind
Study ID Pro00009633
Principal investigator
Joanne Weidhaas, MDPhD
MiraKind
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.